AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02596074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omiganan (CLS001) topical gel
Study NCT03153358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: icotinib 125 milligram three times a day
Study NCT04165668 — intervention group
Intervention type: OTHER
Intervention: Exposure: First on scene
Description: To be first on scene for resuscitation at the suspected out-of hospital cardiac arrest, before EMS and first responders (fire and police services)
Study NCT02992392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposic
Description: one eye of the participant recieved Lipoic
Study NCT02596074 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle topical gel
Study NCT01522066 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perineural catheter
Description: Patients in the experimental group will receive a single dose of local anesthetic though an indwelling catheter both before and after surgery.
Study NCT03153358 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: given radiation for the primary lesion
Study NCT04348877 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Antibody-Rich Plasma from COVID-19 recovered patients
Description: 400 millimeter of Antibody-Rich Plasma from COVID-19 recovered patients will be transfused to patients with severe or immediately life-threatening COVID-19
Study NCT03955406 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Low flow Anesthesia
Description: During the initial wash-in period 4 L/min Fresh gas flow will be used.
Study NCT02992392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tears Naturale Forte
Description: the other eye of the participant recieved Tears Naturale Forte
Study NCT01447732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-37250/KHK2804
Description: Part 1 is based on the CEP-37250/KHK2804 tolerability and safety data from three subjects enrolled in a cohort, enrollment at the next dose level or additional subjects into the ongoing cohort will occur based upon the number subjects with DLT at a given dose level. Dose depends on subject's body weight. Part 1 includes intervention of CEP-37250/KHK2804.~Part 2 will receive CEP-37250/KHK2804 at a dose to be determined following completion of Part 1.
Study NCT03955406 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low Flow Anesthesia with fixed fresh gas flow rate
Description: Fresh gas flow rate will be 1 L/min throughout the procedure.
Study NCT02385539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The impact of 10 independent variables on the likelihood of not developing hypotension after intrathecal injection.
Description: The study will be conducted to assess the impact of a 10 independent variables (dose and combination of Levobupivacaine with Fentanyl or Sufentanil, age, basal systolic blood pressure (SBP), basal mean arterial pressure (MAP), time to lowest spinal SBP, upper limit of sensory block (dermatoma level), time intervals of sensory recovery for two consecutive dermatoma level (two-segment regression), time intervals of sensory recovery to the twelfth thoracic dermatoma (T12 regression), time intervals of sensory recovery to the first sacral dermatoma (S1 regression) and Body Mass Index) on the likelihood of not developing hypotension after intrathecal injection.
Study NCT02385539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The impact of 10 independent variables on the likelihood of not developing hypotension after intrathecal injection.
Description: The study will be conducted to assess the impact of a 10 independent variables (dose and combination of Levobupivacaine with Fentanyl or Sufentanil, age, basal systolic blood pressure (SBP), basal mean arterial pressure (MAP), time to lowest spinal SBP, upper limit of sensory block (dermatoma level), time intervals of sensory recovery for two consecutive dermatoma level (two-segment regression), time intervals of sensory recovery to the twelfth thoracic dermatoma (T12 regression), time intervals of sensory recovery to the first sacral dermatoma (S1 regression) and Body Mass Index) on the likelihood of not developing hypotension after intrathecal injection.
Study NCT00113529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib + Sunitinib
Description: Until disease progression or unacceptable toxicity.
Study NCT03066986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delta-inulin
Description: Addition of adjuvant, delta-inulin to JJA VIT regime, to determine if this will allow lower doses and shorter regimes to promote protective responses, reducing costs and morbidity of JJA VIT.
Study NCT03066986 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose finding comparison
Description: Define minimum effective maintenance dose (50mcg vs 25mcg). In real world sting challenges after 12 months of JJA VIT objective systemic reaction rates after 50 and 100 mcg maintenance doses respectively 14/130 and 12/126 subjects vs reaction rates to stings in similar subjects without JJA VIT 70-76%. Venom delivery in sting likely \<20mcg. Therefore minimum effective maintenance dose not yet defined.
Study NCT03066986 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dose finding comparison
Description: Define minimum effective maintenance dose (50mcg vs 25mcg). In real world sting challenges after 12 months of JJA VIT objective systemic reaction rates after 50 and 100 mcg maintenance doses respectively 14/130 and 12/126 subjects vs reaction rates to stings in similar subjects without JJA VIT 70-76%. Venom delivery in sting likely \<20mcg. Therefore minimum effective maintenance dose not yet defined.
Study NCT01086514 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual Energy Contrast Enhanced Digital Mammography (DE CEDM)
Description: Each patient will have: Bilateral digital mammography, Bilateral Breast MRI, Bilateral Contrast Enhanced Digital Mammography. The latter examination is the only change in patient management. An additional contrast injection is involved. Results of the DE CEDM will be compared with routine digital mammography and breast MRI. The reference standard is pathology. If surgery is to be done; every attempt will be made to perform all imaging exams within 30 days.
Study NCT03398889 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma levels of metabolites
Description: plasma levels of metabolites
Study NCT03084835 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Brief cessation counseling
Study NCT03084835 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WEB+TXT
Description: Access to Become an Ex website plus text messaging
Study NCT03035331 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Undergo cryosurgery
Study NCT03035331 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Therapy
Description: Given IT
Study NCT03035331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03035331 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03035331 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent Conjugate Vaccine
Description: Given by injection
Study NCT03035331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04428723 — intervention group
Intervention type: OTHER
Intervention: Entry of demographic and medical history data into a deidentified database
Description: Entry into repository for analysis.
Study NCT04428723 — intervention group
Intervention type: GENETIC
Intervention: Blood sample for DNA analysis
Description: Targeted resequencing of DNA to identify variants associated with hypoglycemia, comparing participants with hypoglycemia (both surgical and non-surgical) and healthy controls.
Study NCT04428723 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Stool sample for microbiome analysis
Description: Participants will be asked to provide a fecal sample, collected at home, which will be analyzed to determine the types of bacteria present in the feces.
Study NCT04428723 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Mixed meal tolerance test
Description: For a subset of participants: After an overnight fast, participants will be given a standard liquid mixed meal; blood samples will be collected at baseline (fasting) and at defined time points after a meal for metabolic and hormonal analyses.
Study NCT03084835 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WEB+TXT+TTS
Description: Access to Become an Ex website plus text messaging plus consult with a trained tobacco treatment specialist
Study NCT03398889 — intervention group
Intervention type: BEHAVIORAL
Intervention: Dietary questionnaire
Description: Harvard food frequency questionnaire
Study NCT03888846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Topical gel version of pentoxifylline to be administered intraorally.
Study NCT03888846 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Colchicine
Description: Colchicine therapy is provided to patients with oral ulcers as part of supportive care routinely offered by Behcet's Clinic-Istanbul.
Study NCT03888846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine therapy is provided to patients with oral ulcers as part of supportive care routinely offered by Behcet's Clinic-Istanbul.
Study NCT01375946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG200-15
Description: There will be three treatment periods. Subjects will be randomly assigned to one of the five conditions for the treatment period. The subject will be exposed daily to the condition assigned while wearing the patch. The study patch will be worn for a 7 day treatment period, followed by a 7 day washout period. The total duration of the study is 6 weeks.
Study NCT03398889 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intestinal microbiome
Description: amplification and sequencing of 16S rRNA gene variable regions in stool samples
Study NCT04428723 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Continuous glucose monitoring
Description: A CGM sensor (Dexcom G4 or other professional version available at onset of study) will be placed in blinded (masked) mode, and will be worn for 10 days. Data will be analyzed to determine patterns of glucose during both day and night intervals.
Study NCT01817439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone
Description: patients will be randomly assigned to oral OR IV Amiodarone
Study NCT04428723 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: activity monitor
Description: The activity monitor (Fitbit Charge 2) will be worn by participants for 10 days, to assess activity, concurrent with CGM sensor wear.
Study NCT00785473 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: cholecalciferol capsules, 20,000 IU weekly for 2 years and calcium carbonate 500 mg daily
Study NCT00785473 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: calcium carbonate
Description: calcium carbonate 500 mg daily for 2 years
Study NCT00785473 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: calcium carbonate
Description: calcium carbonate 500 mg daily for 2 years
Study NCT03990428 — intervention group
Intervention type: BEHAVIORAL
Intervention: online surveys
Description: Survey data about supportive care needs, mood, and the experience of IC's finding meaning and purpose in the caregiving experience.
Study NCT01435135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV
Description: 1 mL per injection containing 10\^6 CCID50/dose administered
Study NCT01435135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E
Description: 1 mL per injection (300 ug dose/antigen for a total of 600ug/dose administered)
Study NCT01435135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV Placebo
Description: 1 ml per injection
Study NCT01435135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E Placebo
Description: 1 ml per injection
Study NCT00580385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue Procurement
Description: MTX polyglutamylation, MTX transport, XTT cytotoxicity assays, Quantitative RT-PCR, Southern blotting, Mutation detection, and Western blotting
Study NCT00310596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
Description: 0,1mmol/kg at 10 mL/15 sec
Study NCT00310596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
Description: same dose as arm 1 at bolus rate (2mL/sec)
Study NCT00310596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
Description: 0,3mmol/kg at 10 mL/15 sec
Study NCT00310596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
Description: same dose as arm 3 at bolus rate (2mL/sec)
Study NCT00310596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin (BAY12-8039)
Description: 400 mg at 0,07 mL/sec over 60 min
Study NCT00310596 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0,9% saline at 0,6mL/kg at bolus rate
Study NCT03225378 — intervention group
Intervention type: OTHER
Intervention: Fluid loading of 500 mL of crystalloid solution
Description: Infusion of 500 mL of crystalloid solution in less than 15 minutes
Study NCT03225378 — intervention group
Intervention type: OTHER
Intervention: Passive Leg Raising test
Description: This intervention is done before the fluid loading in order to predict fluid responsiveness.
Study NCT01995396 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: APE with intersphincteric dissection
Description: Abdominal operation where the rectum is resected down to the levator and then the anus is resected by an intersphincteric dissection and order to leave the outer sfincter and levator in place to avoid a large wound and a high rate of infectious complications.
Study NCT01995396 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hartmann´s procedure
Description: Abdominal operation where the rectum is resected and stapled off distally and a stoma is created
Study NCT03086252 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Red Blood Cell Transfusions (RBCT)
Description: Undergo patient-driven RBCT
Study NCT01149720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib (ARQ 197) Capsule
Description: Oral BID 360 mg dose (Capsule C: 6 X 60 mg) of ARQ 197 at least 1 hour before or 2 hours after a meal for 7 days
Study NCT01149720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib (ARQ 197) Tablet
Description: Oral BID 360 mg dose (Tablet: 3 x 120 mg) of ARQ 197 under fed conditions for 7 days
Study NCT01149720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib (ARQ 197) Capsule D, oral
Description: Oral BID 360 mg dose (Capsule D: 3 x 120 mg) of ARQ 197 under fed conditions in the extension phase
Study NCT01700543 — intervention group
Intervention type: PROCEDURE
Intervention: Shoulder Arthroplasty
Description: Implantation of the Sidus Stem-Free Shoulder follows standard shoulder replacement procedures.
Study NCT01522066 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-shot block
Description: Patients in the control group will receive a single shot of local anesthetic, in standard fashion, before surgery.
Study NCT03377218 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iodine
Description: Receiving 150 μg iodine (as potassium iodide) daily
Study NCT03377218 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iodine + Selenium
Description: Receiving a combination of 150 μg iodine (as potassium iodide) and 100 μg selenium daily
Study NCT03639025 — intervention group
Intervention type: DEVICE
Intervention: OCS Lung System
Description: The OCS™ Lung System is a portable organ perfusion, ventilation, and monitoring medical device intended to preserve donor lungs in a near physiologic, ventilated, and perfused state prior to transplantation. This technology was designed to overcome the limitation of cold storage and has the potential to expand the utilization of donor lungs. The OCS™ Lung System accomplishes this by performing 3 key functions:~* Reducing ischemic injury through the use of warm, oxygenated blood based perfusion.~* Optimizing the lung condition by ventilatory recruitment maneuvers and high-oncotic perfusion solution supplemented with hormones and nutrients.~* Allowing for ex-vivo functional assessment of the donor lung during preservation and prior to transplant.
Study NCT04068116 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary per-cutaneous coronary intervention
Description: Patients presenting with ST-elevation myocardial infarction will undergo primary per-cutaneous coronary intervention including balloon angioplasty \& coronary stent deployment as needed +/- post-conditioning (for post-conditioning arm) making 4 cycles of repeated occlusion \& reperfusion 30-second each by inflation/deflation of an appropriately sized PTCA (percutaneous transluminal coronary angioplasty) balloon
Study NCT04068116 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary per-cutaneous coronary intervention
Description: Patients presenting with ST-elevation myocardial infarction will undergo primary per-cutaneous coronary intervention including balloon angioplasty \& coronary stent deployment as needed +/- post-conditioning (for post-conditioning arm) making 4 cycles of repeated occlusion \& reperfusion 30-second each by inflation/deflation of an appropriately sized PTCA (percutaneous transluminal coronary angioplasty) balloon
Study NCT04153916 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Neurotrigger eye blinking stimulator
Description: Phase 1 - The first stage is composed of a one-time participation for about three hours and involves:~1. Verifying compliance of the patients with the research inclusion and exclusion criteria~2. Completion of the study clinical report form (CRF) for this stage~3. Placement of the single use mini-electrodes that will be adhered to the facial skin near the non-blinking eye and coupled to the Neurotrigger stimulator to elicit eyelid closure.~Participants may be enrolled to the second phase up to one year from the first phase visit In the second stage the duration of the participation is about three weeks (six days a week) and includes daily use of the device for up to 10 hours a day. During nights the patient will continue is standard pattern of either eye closure or leaving the eye open, as the patient used to do prior to the study.~This stage will involve a patient with a partner that is designated to support the patient closely during the placement and adjustment of the system
Study NCT03682692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACEI/CCB
Description: benazepril 10 mg / amlodipine besylate 5 mg fixed-dose combination
Study NCT03682692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACEI/DIU
Description: benazepril 10 mg / hydrochlorothiazide 12.5 mg fixed-dose combination
Study NCT06094790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125134 150 mg
Description: CORT125134 150 mg (3 X 50 mg current capsule formulation)
Study NCT06094790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125134 250 mg
Description: CORT125134 250 mg (5 X 50 mg current capsule formulation)
Study NCT06094790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125134 dose to be determined
Description: CORT125134 current capsule formulation, dose to be determined
Study NCT03562494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VY-AADC02
Description: Adeno-associated viral vector serotype 2 encoding human aromatic L-amino acid decarboxylase (AAV2- hAADC) infusion into the brain
Study NCT03562494 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham (Placebo) Surgery
Description: Bilateral partial burr/twist holes without dura penetration
Study NCT02687139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Study NCT02687139 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Positron Emission Tomography - Computed Tomography (PET/CT)
Study NCT03068754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar
Description: Repository corticotropin for subcutaneous injection
Study NCT03068754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for subcutaneous injection
Study NCT03068754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for subcutaneous injection
Study NCT04099121 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound Imaging
Description: 3D ultrasound of the pelvic floor and vaginal cavity will be obtained by using a commercial ultrasound system.